Trial Information
National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)
Inclusion Criteria:
- Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
- Patient examined AND with a routine blood test planned
- Patient informed of procedure for the study who was not opposed to it
Exclusion Criteria:
- Patient treated for malignant hemopathy
- Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
- Patients with no routine blood laboratory tests planned
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To evaluate the prevalence of the CPK increase
Outcome Description:
Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value > USL
Outcome Time Frame:
Within 3 days after a clinical exam
Safety Issue:
No
Principal Investigator
Antoine ADENIS, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Centre Oscar Lambret
Authority:
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
Study ID:
TKI-CPK 1003
NCT ID:
NCT01248429
Start Date:
November 2010
Completion Date:
February 2011
Related Keywords:
- Cancer
- Solid Tumor
- thyrosine kinase inhibitor
- phosphokinase creatinin
- myalgia
- Neoplasms